Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1225

Sort by

Sort Order Select

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

Wen-Bing Ma, Xiao-Han Wang, Chang-Yan Li, Huan-Huan Tian, Jie Zhang, Jun-Jie Bi, Guang-Ming Ren, Shou-Song Tao, Xian Liu, Wen Zhang, Dong-Xu Li, Hui Chen, Yi-Qun Zhan, Miao Yu, Chang-Hui Ge, Xiao-Ming Yang, Rong-Hua Yin

Blood (2020) 135 (25): 2302–2315.

https://doi.org/10.1182/blood.2019003867

Published: 2020

Includes: Supplemental data

Journal Articles

Carfilzomib Induces Cardiotoxicity Via ß5/ß2-Specific Proteasome Subunit Inhibition Pattern

Max A Mendez-Lopez, MD, Andrej Besse, PhD, Bogdan Florea, PhD, Christian Zuppinger, PhD, Herman Overkleeft, PhD, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2019) 134 (Supplement_1): 3110.

https://doi.org/10.1182/blood-2019-127987

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Wilson I Gonsalves, MD, Srinivas Devarakonda, MD, Rachid Baz, MD, Natalia Neparidze, MD, Alex A Adjei, MD PhD, Charles Kunos, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3160.

https://doi.org/10.1182/blood-2019-123399

Published: 2019

Journal Articles

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

Dipenkumar Modi, MD, Seongho Kim, PhD, Jie Chi, MD, Lois Ayash, MD, Asif Alavi, MD, Andrew Kin, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2019) 134 (Supplement_1): 3311.

https://doi.org/10.1182/blood-2019-124838

Published: 2019

Journal Articles

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Nikolaos Trasanidis, Alexia Katsarou, Bien Bergonia, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Reema Paudel, Xiaolin Xiao, Holger W Auner, MD PhD, Irene Roberts, Kikkeri Naresh, MD, Aristeidis Chaidos, Luca Magnani, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3760.

https://doi.org/10.1182/blood-2019-124109

Published: 2019

Journal Articles

Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications

Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Huihui Tang, PhD, Brian Glassner, PhD, Olga Dashevsky, PhD, Minasri Borah, Megan Bariteau, B.Sc., Richard Groen, John G Doench, PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 315.

https://doi.org/10.1182/blood-2019-127502

Published: 2019

Journal Articles

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

Ursula S.A. Stalmann, MD, Fabio Ticconi, MSc, Ronghui Li, MSc, Aaron B. Wong, PhD, Glenn Cowley, PhD, David E. Root, PhD, Dirk Heckl, PhD, Inge Snoeren, MSc, Sergio Martinez, PhDMSc, Tim H Brümmendorf, MD, Andreas Schuppert, PhD, Ivan Costa, PhD, Benjamin L. Ebert, MD PhD, Rebekka K. Schneider, MD PhD

Blood (2019) 134 (Supplement_1): 559.

https://doi.org/10.1182/blood-2019-122588

Published: 2019

Journal Articles

The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis

Taishi Yonezawa, MSc, Hirotaka Takahasi, PhD, Tatsuya Sawasaki, PhD, Toshio Kitamura, MD PhD, Susumu Goyama, MD PhD

Blood (2019) 134 (Supplement_1): 1252.

https://doi.org/10.1182/blood-2019-126264

Published: 2019

Journal Articles

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Fabian Freisleben, Hauke Stamm, PhD, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, MD, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2019) 134 (Supplement_1): 5050.

https://doi.org/10.1182/blood-2019-129973

Published: 2019

Journal Articles

Selective Dependency of MLL-Rearranged Leukemia on Immunoproteasome Function

Nuria Tubío Santamaría, Jonas Tönsing, Tina M. Schnoeder, PhD, Ulrike Seifert, Clemens Cammann, Juliane Mohr, PhD, Aniruddha J. Deshpande, PhD, Joanna Kirkpatrick, Alessandro Ori, PhD, Florian Perner, MD, Florian H. Heidel, MD

Blood (2019) 134 (Supplement_1): 529.

https://doi.org/10.1182/blood-2019-122100

Published: 2019

Journal Articles

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Megan Bariteau, BSc, Minasri L. Borah, Sam Bender, Janaka Foneska, Jennifer Roth, Richard Groen, Gina Walter, Manja Friese-Hamim, Samantha M. Goodstal, Michael Sanderson, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 1291.

https://doi.org/10.1182/blood-2019-130356

Published: 2019

Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 174.

https://doi.org/10.1182/blood-2019-126921

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Leah Fung, PhD, Aparajita Hoskote Chourasia, PhD, Eduardo Torres, MSc, Imelda Lam, BSc, Paul Erdman, MSc, David Hecht, PhD, Robert Sullivan, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Avanthika Venkatachalam, MSc, Irit Snir-Alkalay, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, Yinon Ben-Neriah, MD PhD, David I Stirling, PhD

Blood (2019) 134 (Supplement_1): 4643.

https://doi.org/10.1182/blood-2019-131834

Published: 2019

Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Blood (2019) 134 (Supplement_1): 5493.

https://doi.org/10.1182/blood-2019-125447

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

NARROW

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

A master erythroid regulator gets its own GPS

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

Carfilzomib Induces Cardiotoxicity Via ß5/ß2-Specific Proteasome Subunit Inhibition Pattern

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall Survival

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

The Ubiquitin Ligase DTX2 Promotes Nuclear Export of RUNX1 and Inhibits RUNX1-Dependent Leukemogenesis

Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting

Selective Dependency of MLL-Rearranged Leukemia on Immunoproteasome Function

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only